All News

Key updates from the Seattle, WA, conference in March.

Evenity (romosozumab-aqqg) has been approved to treat postmenopausal women at high risk of bone fractures.

Women no longer require nine months of contraception post cessation of the drug.

Like the idea of telpharmacy and not sure where to start? 

First-ever dual-drug, single tablet for HIV offers lighter treatment regimen. 

Advocates are calling for government regulations on PBMs and pharmacy.  

Consumers are using test strips that might lead to inaccurate results. 

Rural markets pave way to treat underserved populations, provide value-based care, and expand prescription volume. 

New report highlights the dangers of prescription medications beyond opioids. 

"Test and treat" scheme reducing stress on general practitioners. 

The program increased hypertension management rates to 77% in 2017. 

Tom Kraus to bring expeirence in government and industry.

Two Arizona pharmacists made headlines when it seems they may have not adhered to the Oath of the Pharmacist.

Success depends on marketing, relationship building. 

Solriamfetol is approved for adult patients suffering from the effects of narcolepsy and OSA. 

The CBD market is anticipated to be worth $20 billion by 2024.

New guide details actions for pharmacists and payers.

The next-generation oral drug is the first to be approved specifically for secondary progressive multiple sclerosis in more than 15 years.

 More than 25,000 lawsuits cite uncontrollable and irreversible bleeding and death. 

Patients taking PPIs 28.4 times more likely to develop chronic kidney disease. 

The groups say the state has intentionally suppressed dispensing fees to reimburse pharmacies that service Medicaid patients.

Effective management strategies are needed for medications billed through medical benefits.

Researchers targeting virus' receptors used to enter the body. 

First drug approved for PPD use to remain under REMS program.